Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

281 trials

2025-523061-22-00
Recruiting
A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatment of Patients with Autoimmune B-Cell driven Diseases including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Granulomatous Polyangiitis (GPA), BlinA-B trial
Phase 2 · Germany · 1 site
Registry update: 2 Oct 2026
NCT07085104
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Phase 1 · Canada, United States · 18 sites
Registry update: 2 Nov 2026
NCT07236801
Recruiting
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Phase 1 · China · 1 site
Registry update: 2 Mar 2026
NCT06795893
Recruiting
The Anifrolumab PRIM Program
Not applicable · Sweden · 1 site
Registry update: 11 Sept 2026
NCT07233642
Recruiting
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
Phase 1 · China · 1 site
Registry update: 18 Nov 2025
NCT07829614
Recruiting
F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus
Phase 1 · China · 1 site
Registry update: 21 Sept 2026
NCT07109986
Recruiting
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
Phase 1 · China · 1 site
Registry update: 23 Jan 2026
NCT07175285
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Not applicable · Argentina, Brazil, Canada, Germany, Spain, France, United Kingdom, Israel, Italy, Japan, Puerto Rico, Sweden, United States · 70 sites
Registry update: 2 Nov 2026
NCT07352332
Recruiting
Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE
Not applicable · China · 1 site
Registry update: 20 Jan 2026
NCT07185269
Recruiting
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
Phase 1/2 · China · 1 site
Registry update: 26 Nov 2025
NCT07193810
Recruiting
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
Early phase 1 · China · 1 site
Registry update: 14 Apr 2026
NCT07053891
Recruiting
LUPKYNIS Drug-use Results Survey
Not applicable · Japan · 1 site
Registry update: 20 Oct 2026
NCT07177911
Recruiting
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
Phase 1 · China · 1 site
Registry update: 17 Sept 2025
NCT07115745
Recruiting
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Phase 1 · Australia, Brazil, Czechia, Germany, Spain, France, Israel, Poland, Romania, United States · 28 sites
Registry update: 14 Jul 2026
NCT07215663
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
Phase 1 · China · 17 sites
Registry update: 2 Sept 2026
NCT07174843
Recruiting
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
Early phase 1 · China · 1 site
Registry update: 16 Sept 2025
NCT06977724
Recruiting
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
Phase 1 · France, Netherlands, United States · 11 sites
Registry update: 10 Aug 2026
NCT07010835
Recruiting
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
Phase 1/2 · China · 1 site
Registry update: 5 Feb 2026
NCT07077486
Recruiting
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
Phase 4 · China · 1 site
Registry update: 27 Jan 2026
NCT07121777
Recruiting
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
Not applicable · China · 1 site
Registry update: 13 Aug 2025

Ordered by registry start date. Freshness and sponsorship never change the order.